Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 12, Pages e003790
Publisher
BMJ
Online
2021-12-22
DOI
10.1136/jitc-2021-003790
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
- (2021) Feng-Hua Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- 858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)
- (2021) A.T. Chan et al. ANNALS OF ONCOLOGY
- Cancer Cell–Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti–PD-1 Therapy in Lung Adenocarcinoma
- (2020) Amber M. Johnson et al. JOURNAL OF IMMUNOLOGY
- Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
- (2020) Pok Man Hau et al. Frontiers in Oncology
- Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
- (2020) Jeffrey C Thompson et al. Journal for ImmunoTherapy of Cancer
- Relationship of Circulating Tumor Cells and Epstein‐Barr Virus DNA to Progression‐Free Survival and Overall Survival in Metastatic Nasopharyngeal Carcinoma Patients
- (2019) Rui You et al. INTERNATIONAL JOURNAL OF CANCER
- MHC-II neoantigens shape tumour immunity and response to immunotherapy
- (2019) Elise Alspach et al. NATURE
- Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma
- (2018) Noppadol Larbcharoensub et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
- (2018) Brigette B.Y. Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial
- (2018) Anthony T.C. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- (2018) Wenfeng Fang et al. LANCET ONCOLOGY
- Biological Consequences of Major Histocompatibility Class-II Expression by Tumor Cells in Cancer
- (2018) Margaret L Axelrod et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- (2017) Chiun Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
- (2017) Yvonne Y Li et al. Nature Communications
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
- (2017) Patricia Gaule et al. JAMA Oncology
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1
- (2015) J.-H. Lin et al. BLOOD
- The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma
- (2015) Li-Ting Liu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma
- (2015) Jianwei Zhang et al. MEDICAL ONCOLOGY
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- The role of Epstein-Barr virus in epithelial malignancies
- (2014) Sai-Wah Tsao et al. JOURNAL OF PATHOLOGY
- Down-Regulation of MHC Class II Expression through Inhibition of CIITA Transcription by Lytic Transactivator Zta during Epstein-Barr Virus Reactivation
- (2009) D. Li et al. JOURNAL OF IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now